07:00 , Sep 23, 2013 |  BC Week In Review  |  Company News

Chiesi, Cornerstone Therapeutics deal

Chiesi will acquire the 42% of shares of partner Cornerstone it does not already own for $9.50 per share in cash. The deal values Cornerstone at about $255.3 million based on 26.9 million shares outstanding...
07:00 , Sep 23, 2013 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Algeta ASA (OSE:ALGETA) added NOK3.40 to NOK244.40 on Friday after EMA's CHMP recommended approval of Xofigo radium-223 dichloride to treat adults with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral...
01:04 , Sep 17, 2013 |  BC Extra  |  Company News

Chiesi to acquire Cornerstone

Chiesi Farmaceutici S.p.A. (Parma, Italy) will acquire the 42% of shares of partner Cornerstone Therapeutics Inc. (NASDAQ:CRTX) it does not already own for $9.50 per share in cash. The deal values Cornerstone at about $255.3...
08:00 , Feb 25, 2013 |  BC Week In Review  |  Company News

Chiesi, Cornerstone Therapeutics deal

Cornerstone said its board received a proposal from partner Chiesi to take Cornerstone private. Chiesi, which owns about 60% of Cornerstone, is proposing to acquire all of the Cornerstone shares it does not already own...
08:00 , Feb 25, 2013 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Alexza Pharmaceuticals Inc. (NASDAQ:ALXA) was off $0.14 to $4.47 last week after the European Commission approved an MAA for Adasuve Staccato to treat mild to moderate agitation in adults with schizophrenia or bipolar...
01:38 , Feb 21, 2013 |  BC Extra  |  Company News

Cornerstone receives proposal to go private

Cornerstone Therapeutics Inc. (NASDAQ:CRTX) said its board received a proposal from partner Chiesi Farmaceutici S.p.A. (Parma, Italy) to take Cornerstone private. Chiesi, which owns about 60% of Cornerstone, is proposing to acquire all of the...
07:00 , May 21, 2012 |  BioCentury  |  Finance

Fattening up the obesity arena

Investors in last week's $60.5 million follow-on for Arena Pharmaceuticals Inc. (NASDAQ:ARNA) could see their bet play out in short order as the obesity play has a June 27 PDUFA date for lorcaserin. Arena sold...
07:00 , Mar 12, 2012 |  BioCentury  |  Emerging Company Profile

Airway: Pulmonary D-fense

Products containing surfactant proteins B and C have reduced mortality caused by respiratory distress syndrome in premature newborns, but chronic bronchopulmonary dysplasia caused by ventilation remains a problem. Airway Therapeutics LLC has shown adding surfactant...
07:00 , Mar 12, 2012 |  BioCentury  |  Finance

Argos plowing ahead

Argos Therapeutics Inc. is being coy about its financing plans after withdrawing its planned IPO on NASDAQ due to market conditions. But the company says it is going ahead next quarter with a $40-$50 million...
08:00 , Nov 7, 2011 |  BioCentury  |  Finance

Clovis closes in

Clovis closes in Clovis Oncology Inc. is aiming for the largest IPO by a therapeutics company since the $215.6 million debut for gastrointestinal play Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) in February 2010. Clovis began its road...